Citigroup Inc Atai Life Sciences N.V. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Citigroup Inc holds 2,979 shares of ATAI stock, worth $3,545. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,979

Previous 3,546 15.99%

Holding current value

$3,545

Previous $4,000 25.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$1.16 - $1.64 $657 - $929	-567 Reduced 15.99%	2,979 $3,000
Q2 2024 Aug 12, 2024	BUY	$1.27 - $2.6 $3,434 - $7,030	2,704 Added 321.14%	3,546 $4,000
Q1 2024 May 10, 2024	SELL	$1.5 - $2.19 $3,586 - $5,236	-2,391 Reduced 73.96%	842 $1,000
Q4 2023 Feb 09, 2024	BUY	$1.04 - $1.55 $982 - $1,464	945 Added 41.3%	3,233 $4,000
Q3 2023 Nov 09, 2023	SELL	$1.27 - $2.28 $10,534 - $18,912	-8,295 Reduced 78.38%	2,288 $2,000
Q2 2023 Aug 10, 2023	BUY	$1.44 - $2.19 $8,019 - $12,196	5,569 Added 111.07%	10,583 $18,000
Q1 2023 May 11, 2023	SELL	$1.17 - $2.7 $283 - $653	-242 Reduced 4.6%	5,014 $9,000
Q4 2022 Feb 09, 2023	SELL	$2.38 - $3.55 $77,745 - $115,964	-32,666 Reduced 86.14%	5,256 $13,000
Q3 2022 Nov 10, 2022	SELL	$3.14 - $4.87 $2,351 - $3,647	-749 Reduced 1.94%	37,922 $126,000
Q2 2022 Aug 10, 2022	SELL	$3.03 - $5.32 $5,163 - $9,065	-1,704 Reduced 4.22%	38,671 $141,000
Q1 2022 May 12, 2022	SELL	$4.66 - $7.66 $266,878 - $438,688	-57,270 Reduced 58.65%	40,375 $206,000
Q4 2021 Feb 10, 2022	BUY	$6.82 - $17.8 $271,204 - $707,834	39,766 Added 68.71%	97,645 $745,000
Q3 2021 Nov 10, 2021	BUY	$13.62 - $19.48 $788,311 - $1.13 Million	57,879 New	57,879 $856,000

Others Institutions Holding ATAI

# of Institutions

Shares Held

12.4M

Call Options Held

77.8K

Put Options Held

50.3K

View Full List

About ATAI Life Sciences N.V.

Ticker ATAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 165,875,008
Market Cap $197M
Description
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...

More about ATAI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account